BR9913948A - Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda - Google Patents

Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda

Info

Publication number
BR9913948A
BR9913948A BR9913948-0A BR9913948A BR9913948A BR 9913948 A BR9913948 A BR 9913948A BR 9913948 A BR9913948 A BR 9913948A BR 9913948 A BR9913948 A BR 9913948A
Authority
BR
Brazil
Prior art keywords
treatment
acute pain
fentanyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR9913948-0A
Other languages
English (en)
Other versions
BR9913948B1 (pt
Inventor
Anders Pettersson
Nyrstroem Christer
Hans Lennernos
Bo Lennernos
Thomas Hedner
Original Assignee
Diabact Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Diabact Ab filed Critical Diabact Ab
Publication of BR9913948A publication Critical patent/BR9913948A/pt
Publication of BR9913948B1 publication Critical patent/BR9913948B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE DOR AGUDA POR ADMINISTRAçãO SUBLINGUAL, USO DE FENTANILA OU UM SAL FARMACEUTICAMENTE ACEITáVEL DA MESMA, E PROCESSO PARA O TRATAMENTO DE DOR AGUDA" Uma composição farmacêutica para o tratamento de dor aguda por administração sublingual é descrita. A composição compreende uma mistura ordenada, essencialmente isenta de água, de fentanila ou um sal farmaceuticamente aceitável da mesma, na forma de micro partículas que são aderidas à superfície das partículas portadoras que são substancialmente maiores do que as partículas de fentanila, e são essencialmente solúveis em água em água. Em uma forma de realização preferida, a composição também contém um agente promotor de bioadesão e/ou mucoadesão. A invenção também se refere à preparação da composição, e ao uso de composição para o tratamento de dor aguda.
BRPI9913948-0A 1998-09-24 1999-09-24 composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e, uso de uma composição farmacêutica essencialmente isenta de água. BR9913948B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803239A SE9803239D0 (sv) 1998-09-24 1998-09-24 Composition for the treatment of acute pain
SE9803239-4 1998-09-24
PCT/SE1999/001688 WO2000016751A1 (en) 1998-09-24 1999-09-24 Fentanyl composition for the treatment of acute pain

Publications (2)

Publication Number Publication Date
BR9913948A true BR9913948A (pt) 2001-06-12
BR9913948B1 BR9913948B1 (pt) 2011-02-08

Family

ID=20412701

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913948-0A BR9913948B1 (pt) 1998-09-24 1999-09-24 composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e, uso de uma composição farmacêutica essencialmente isenta de água.

Country Status (26)

Country Link
US (1) US6759059B1 (pt)
EP (1) EP1115384B1 (pt)
JP (2) JP2002526440A (pt)
KR (1) KR100760531B1 (pt)
CN (1) CN1170524C (pt)
AT (1) ATE247950T1 (pt)
AU (1) AU764473B2 (pt)
BG (1) BG65363B1 (pt)
BR (1) BR9913948B1 (pt)
CA (1) CA2345064C (pt)
CZ (1) CZ301562B6 (pt)
DE (1) DE69910803T2 (pt)
DK (1) DK1115384T3 (pt)
EE (1) EE200100176A (pt)
ES (1) ES2207295T3 (pt)
HU (2) HU230688B1 (pt)
IL (2) IL142126A0 (pt)
NO (1) NO332228B1 (pt)
NZ (1) NZ510646A (pt)
PL (1) PL197078B1 (pt)
PT (1) PT1115384E (pt)
RU (1) RU2232580C2 (pt)
SE (1) SE9803239D0 (pt)
SK (1) SK283503B6 (pt)
TR (1) TR200100812T2 (pt)
WO (1) WO2000016751A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
IT1318618B1 (it) * 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
DK1307194T4 (da) 2000-07-31 2011-07-18 Nycomed Danmark Aps Fentanylpræparat til nasal administration
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
DE60219124T2 (de) * 2001-11-16 2008-01-31 Randox Laboratories Ltd., Crumlin Verfahren und Kit zum Nachweis, oder zum Quantifizieren von, Metaboliten von Fentanyl und Metaboliten von Fentanyl Analoga
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1587514B3 (en) * 2003-01-31 2011-06-22 Orexo AB A rapid-acting pharmaceutical composition
WO2004080382A2 (en) * 2003-03-11 2004-09-23 Arakis Ltd. Novel compositions containing fentanyl
JP5137286B2 (ja) 2003-06-10 2013-02-06 帝國製薬株式会社 フェンタニル含有口腔粘膜貼付剤
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005065319A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
GB0423800D0 (en) * 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1863456A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
US20060276501A1 (en) * 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
CN101330903B (zh) * 2005-12-13 2015-07-08 生物递送科学国际公司 防滥用的经黏膜给药装置
CN101495080B (zh) * 2006-01-06 2013-10-23 阿塞尔Rx制药有限公司 药物存储及发放装置以及包括该装置的系统
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
DK1976521T3 (en) * 2006-01-25 2015-04-27 Insys Therapeutics Inc Sublingual fentanyl spray
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080090874A1 (en) * 2006-09-20 2008-04-17 Messina John C Jr Treatment of breakthrough pain in patients suffering from chronic low back pain
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
JP5484062B2 (ja) * 2006-12-04 2014-05-07 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
CA2677281C (en) 2007-02-09 2019-10-29 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20080287494A1 (en) * 2007-04-24 2008-11-20 Cephalon, Inc. Transmucosal treatment methods in patients with mucositis
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
PT2180844T (pt) 2007-08-02 2018-04-06 Insys Dev Co Inc Nebulizador sub-lingual de fentanilo
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2295046B1 (de) * 2009-09-14 2012-12-19 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
TR201902233T4 (tr) 2009-10-30 2019-03-21 Ix Biopharma Ltd Hızlı çözünen katı dozaj formu.
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
KR101944367B1 (ko) 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
PL2915525T3 (pl) 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
DE102012006396A1 (de) 2012-03-29 2013-10-02 Willy Rüsch GmbH Tracheostomietubus
PL2849730T3 (pl) 2012-05-02 2017-05-31 Orexo Ab Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
MX2015006022A (es) * 2014-02-07 2015-10-14 Scilabs Pharmaceuticals Sistemas de administracion de farmacos sublinguales, totalmente naturales, no toxicos.
US20160144528A1 (en) 2014-11-25 2016-05-26 Biodelivery Sciences International, Inc. Patch devices, methods and apparatus for forming, and testing pharmaceutical agent delivery patch devices
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
JP3836566B2 (ja) * 1996-05-13 2006-10-25 久光製薬株式会社 フェンタニル含有経皮投与テープ製剤
JP3943724B2 (ja) * 1998-07-31 2007-07-11 東光薬品工業株式会社 フェンタニル含有経皮投与マトリックス型貼付剤
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action

Also Published As

Publication number Publication date
AU764473B2 (en) 2003-08-21
CA2345064A1 (en) 2000-03-30
ATE247950T1 (de) 2003-09-15
HU230688B1 (hu) 2017-09-28
DE69910803D1 (de) 2003-10-02
KR100760531B1 (ko) 2007-10-04
TR200100812T2 (tr) 2001-07-23
SK4012001A3 (en) 2001-10-08
HU228992B1 (en) 2013-07-29
JP4478512B2 (ja) 2010-06-09
US6759059B1 (en) 2004-07-06
AU6492899A (en) 2000-04-10
NZ510646A (en) 2004-04-30
NO20011502L (no) 2001-03-23
CA2345064C (en) 2008-05-27
CN1328448A (zh) 2001-12-26
BG105380A (en) 2001-12-29
SK283503B6 (sk) 2003-08-05
ES2207295T3 (es) 2004-05-16
JP2002526440A (ja) 2002-08-20
JP2004269545A (ja) 2004-09-30
PL347467A1 (en) 2002-04-08
WO2000016751A1 (en) 2000-03-30
HUP0103621A3 (en) 2005-05-30
CZ301562B6 (cs) 2010-04-14
RU2232580C2 (ru) 2004-07-20
NO20011502D0 (no) 2001-03-23
IL142126A (en) 2006-04-10
EE200100176A (et) 2002-08-15
SE9803239D0 (sv) 1998-09-24
IL142126A0 (en) 2002-03-10
BG65363B1 (bg) 2008-04-30
HUP0103621A2 (hu) 2002-02-28
KR20010075314A (ko) 2001-08-09
NO332228B1 (no) 2012-07-30
CN1170524C (zh) 2004-10-13
CZ20011030A3 (cs) 2001-09-12
BR9913948B1 (pt) 2011-02-08
EP1115384A1 (en) 2001-07-18
PL197078B1 (pl) 2008-02-29
DK1115384T3 (da) 2003-12-22
EP1115384B1 (en) 2003-08-27
PT1115384E (pt) 2004-01-30
DE69910803T2 (de) 2004-06-17

Similar Documents

Publication Publication Date Title
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
EE04463B1 (et) 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9808812A (pt) Composição compreendendo partìculas cristalinas, finamente divididas de budesonida
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
PT949925E (pt) Preparacao medicinal chato para a aplicacao e a libertacao de buprenorfina ou de uma substancia farmacologicamente comparavel na cavidade bucal e processo para a sua producao
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0016504A (pt) Preparação farmacêutica plana, uso de uma preparação farmacêutica, método para o tratamento de estados de dor e método para o tratamento de dependencia de opiáceo ou cocaìna dentro da estrutura de terapia de substituição ou de alcance de abstinência
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
BR0103169A (pt) Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
BR0311747A (pt) Composição farmacêutica, forma de dose simples ou de múltiplas doses da composição, kit, e, método para tratar doença
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/02/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.